12.03
+0.4(+3.44%)
Currency In USD
| Previous Close | 11.63 |
| Open | 11.7 |
| Day High | 12.05 |
| Day Low | 11.2 |
| 52-Week High | 14.91 |
| 52-Week Low | 3.91 |
| Volume | 1.3M |
| Average Volume | 963,617 |
| Market Cap | 829.2M |
| PE | -4.47 |
| EPS | -2.69 |
| Moving Average 50 Days | 12.67 |
| Moving Average 200 Days | 8.83 |
| Change | 0.4 |
If you invested $1000 in EyePoint Pharmaceuticals, Inc. (EYPT) 10 years ago, it would be worth $310.05 as of October 21, 2025 at a share price of $12.03. Whereas If you bought $1000 worth of EyePoint Pharmaceuticals, Inc. (EYPT) shares 5 years ago, it would be worth $2,559.57 as of October 21, 2025 at a share price of $12.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
EyePoint Announces Pricing of Public Offering
GlobeNewswire Inc.
Oct 15, 2025 2:43 AM GMT
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today a
EyePoint Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
Oct 14, 2025 8:35 PM GMT
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today a
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
GlobeNewswire Inc.
Oct 14, 2025 8:01 PM GMT
– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New preclinical data demonstrates that vorolanib, the activ